Loading
HKSEHealthcareMedical - Distribution
Latest quote
HK$0.405
HK$0.00 · 0.00%
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
Latest quote
HK$0.405
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
Day range
Current HK$0.405
52-week range
Current HK$0.405
Regular session · HKT · Market data may be delayed.
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
Day range
Current HK$0.405
52-week range
Current HK$0.405
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 917.34M CNY | 1.06B CNY | 1.08B CNY | 957.7M CNY | 847.39M CNY |
| Cost of goods sold | 669.44M CNY | 790.64M CNY | 797.99M CNY | 680.07M CNY | 583.79M CNY |
| Gross profit | 247.91M CNY | 270.45M CNY | 280.67M CNY | 277.63M CNY | 263.6M CNY |
| Research and development | 21.8M CNY | 17.59M CNY | 18.84M CNY | 15.52M CNY | 13.41M CNY |
| Selling, general, and administrative | 176.99M CNY | 189.5M CNY | 222.29M CNY | 205.03M CNY | 196.16M CNY |
| Operating expenses | 184.74M CNY | 180.74M CNY | 183.86M CNY | 205.39M CNY | 191.37M CNY |
| Interest income | 4.72M CNY | 6.27M CNY | 2.4M CNY | 1.46M CNY | 1.19M CNY |
| Interest expense | 14.05M CNY | 13.28M CNY | 11.52M CNY | 12.29M CNY | 11.78M CNY |
| Depreciation and amortization | 15.33M CNY | 9.84M CNY | 20.08M CNY | 38.19M CNY | 34.78M CNY |
| Operating income | 63.16M CNY | 89.7M CNY | 96.81M CNY | 72.24M CNY | 72.23M CNY |
| Net income | 11.28M CNY | 41.56M CNY | 38.1M CNY | 22.74M CNY | 30.32M CNY |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.0317
2025 complete year+387.7% since 2021
HK$0.0065
2,021
HK$0.0239
2,022
HK$0.0247
2,023
HK$0.0338
2,024
HK$0.0317
2,025
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 5, 2025 | HK$0.0317Annual | Jun 6, 2025 | Jun 30, 2025 |
Dividend | Jun 3, 2024 | HK$0.0338Annual | Jun 4, 2024 | Jun 28, 2024 |
Dividend | Jun 1, 2023 | HK$0.0247Annual | Jun 2, 2023 | Jun 30, 2023 |
Dividend | May 31, 2022 | HK$0.0239Annual | Jun 1, 2022 | Jun 30, 2022 |
Dividend | Jun 1, 2021 | HK$0.0065Annual | Jun 2, 2021 | Jun 30, 2021 |
Dividend | Jun 1, 2020 | HK$0.0234Annual | Jun 2, 2020 | Jun 29, 2020 |
Ex-dividend Jun 5, 2025
HK$0.0317
Annual
Record Jun 6, 2025 · Payment Jun 30, 2025
Ex-dividend Jun 3, 2024
HK$0.0338
Annual
Record Jun 4, 2024 · Payment Jun 28, 2024
Ex-dividend Jun 1, 2023
HK$0.0247
Annual
Record Jun 2, 2023 · Payment Jun 30, 2023
Ex-dividend May 31, 2022
HK$0.0239
Annual
Record Jun 1, 2022 · Payment Jun 30, 2022
Ex-dividend Jun 1, 2021
HK$0.0065
Annual
Record Jun 2, 2021 · Payment Jun 30, 2021
Ex-dividend Jun 1, 2020
HK$0.0234
Annual
Record Jun 2, 2020 · Payment Jun 29, 2020
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
